Lava Therapeutics
Investment area
Venture Investments
Region
Europe
Date of investment
July 2020
Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer.
Investment area
Venture Investments
Region
Europe
Date of investment
July 2020
Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer.